When it comes to MRNA, you just posted=>
If this is the case for MRNA & BNTX which has 14B-15B orders on hand, Most of the top ARKG holdings has no such order book positions and they did not complete phase 3 trials and no FDA, Euro approvals.
How do you feel the ARKG is better for next 5 years that will give you good return better than TQQQ (Leveraged over Nasdaq companies - famous for good profit margins)?